2018 Atherosclerotic Heart Disease Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Atherosclerotic Heart Disease Market

June 2018 | 70 pages | ID: 2E7858430F2EN
VPAResearch

Abstracts

Atherosclerotic heart disease is a heart condition in which plaque piles up in arteries of a patient, which reduces the area for free flow of blood, thereby, causing angina or chest pain. This can eventually turn out to be a heart attack and arrhythmia. With an estimated 18 million population being affected in the US, Atherosclerotic heart disease are among the most rapidly expanding disease in the US and world. Further, the US Atherosclerotic heart disease market is sized at $95 billion during 2017.

To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Atherosclerotic Heart Disease pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Atherosclerotic Heart Disease pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Atherosclerotic Heart Disease pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Contents

1 TABLE OF CONTENTS

1.1 List of LIST OF FIGURES
1.2 List of Tables

2 ATHEROSCLEROTIC HEART DISEASE PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Atherosclerotic Heart Disease Pipeline Snapshot
2.3 Atherosclerotic Heart Disease Pipeline by Phase
2.4 Atherosclerotic Heart Disease Pipeline by Company
2.5 Atherosclerotic Heart Disease Pipeline by Mechanism of Action

3 ATHEROSCLEROTIC HEART DISEASE- COMPANY WISE PIPELINE ANALYSIS

advanceCor GmbH
Angionetics Inc
AngioSoma Inc
APT Therapeutics Inc
Ascendia Pharmaceuticals LLC
AstraZeneca Plc
Bayer HealthCare Pharmaceuticals
Bio-Thera Solutions Ltd
Biscayne Pharmaceuticals Inc
Bracco Imaging S.p.A.
Capricor Therapeutics Inc
CardioVascular BioTherapeutics Inc
CSL Ltd
DalCor Pharmaceuticals Inc
Hemostemix Inc
Idorsia Ltd
Jaan Biotherapeutics LLC
LipimetiX Development Inc
MedImmune LLC
Pharmahungary
Proteon Therapeutics Inc
Recardio, Inc.
Resverlogix Corp
Servier Laboratories Limited
The Medicines Company
Vasade Biosciences
VESSL Therapeutics Ltd
ViroMed Co Ltd
XyloCor Therapeutics Inc
List Continues…

4 ATHEROSCLEROTIC HEART DISEASE R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN ATHEROSCLEROTIC HEART DISEASE PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Atherosclerotic Heart Disease Pipeline by Phase, H2- 2018
Figure 2: Atherosclerotic Heart Disease Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Atherosclerotic Heart Disease Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018

List Of Tables

LIST OF TABLES

Atherosclerotic Heart Disease Pipeline by Phase, H2- 2018
Atherosclerotic Heart Disease Pipeline by Companies, H2- 2018
Atherosclerotic Heart Disease Pipeline by Mechanism of Action, H2- 2018
Table 1: advanceCor GmbH Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 2: Angionetics Inc Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 3: AngioSoma Inc Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 4: APT Therapeutics Inc Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 5: Ascendia Pharmaceuticals LLC Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 6: AstraZeneca Plc Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 7: Bayer HealthCare Pharmaceuticals Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 8: Bio-Thera Solutions Ltd Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 9: Biscayne Pharmaceuticals Inc Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 10: Bracco Imaging S.p.A. Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 11: Capricor Therapeutics Inc Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 12: CardioVascular BioTherapeutics Inc Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 13: CSL Ltd Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 14: DalCor Pharmaceuticals Inc Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 15: Hemostemix Inc Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 16: Idorsia Ltd Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 17: Jaan Biotherapeutics LLC Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 18: LipimetiX Development Inc Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 19: MedImmune LLC Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 20: Pharmahungary Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 21: Proteon Therapeutics Inc Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 22: Recardio, Inc. Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 23: Resverlogix Corp Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 24: Servier Laboratories Limited Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 25: The Medicines Company Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 26: Vasade Biosciences Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 27: VESSL Therapeutics Ltd Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 28: ViroMed Co Ltd Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 29: XyloCor Therapeutics Inc Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018
Table 30: List Continues… Atherosclerotic Heart Disease Pipeline Drugs, H2- 2018